κ-opioid receptor - Wikipedia
Figure 2 from Development of κ opioid receptor antagonists. | Semantic Scholar
Innovation – Cara Therapeutics
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Opioids in cancer: The κ‑opioid receptor (Review)
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Kappa Opiate Receptor Agonist - an overview | ScienceDirect Topics
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain - The Journal of Pain
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension
Antagonists of the kappa opioid receptor - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
κ-opioid receptor - Wikipedia
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Opioid Receptor | kappa, mu Opioid Receptor
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design | Scientific Reports
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
The Kappa Opioid Receptor | SpringerLink
Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists | HTML
Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold | ACS Chemical Neuroscience
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
